Management and prognosis of liver metastasis in breast cancer patients:a report of 163 cases

Jie LI,Xiangdong XU,Nan SHAO,Ying LIN,Xiaoxi LI,Shenming WANG,Weiming LV
DOI: https://doi.org/10.3969/j.issn.1009-976X.2016.05.015
2016-01-01
Abstract:Objective To assess the clinical characteristics , treatment and prognostic factors of liver metastasis in breast cancer patients. Methods One-hundred and sixty-three breast cancer patients with liver metastasis were included in this study from January 2006 to January 2016. The clinical, pathological and treatment information was collected , and the factors related to the survival were evaluated. All statistical analyses were performed using R software. Results The median overall survival of breast cancer with liver metastases was 29.5 (95%CI: 27.8-31.7) months, the median overall survival Group A (initial Stage Ⅳ patients with liver metastases) was 22.1 (95%CI: 17.8-25.1) months, while the median overall survival Group B (relapse with liver metastases) was 34.1 (95%CI: 30.6-37.6) months (P=1.83 ×10-10). If the patients had opportunity to perform local therapy, the prognosis became much better: the median overall survival extended from to 26.4 months to 33.0 months (P=9.95 ×10-3); 1 years, 2 years, 3 years survival rate in Group B are also significantly higher than Group A (Group A: 79.44%, 40.54%, 9.20%; Group B: 98.94%, 84.92%, 40.54%).In univariate analysis, the factors of hormone receptor status, Her-2 expression, Ki67 proliferation, molecular classification, whether multiple liver metastases were limited, and localtherapy opportunity were associated with the prognosis of breast cancer patients with liver metastasis . (P<0.05). In multivariate analysis, the factors of high Her-2 expression, multiple liver metastases were not limited, and no opportunity to do local therapy were independent predictors of poor survival after lung metastases (P<0.05). Conclusion The prognosis of breast cancer patients with liver metastasis is poor. We should pay more attention to the liver screening in order to early detection and early treatment. The preferred treatment is systemic comprehensive treatment. For patients with isolated single liver metastases and good response to systemic treatment , local therapy can obtain good effect.
What problem does this paper attempt to address?